Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 1910 for “"Lymphoma"”.

  1. Mantle cell lymphoma pathogenesis

    Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin’s lymphoma with a median patient survival time of 3 years. Although the characteristic t(11;14)(q13;q32) is found in virtually all cases, experimental evidence suggests that this event alone is insufficient to result in lymphoma and secondary …

    ubc Repository record for Mantle cell lymphoma pathogenesis (opens in a new tab) Download PDF for Mantle cell lymphoma pathogenesis (opens in a new tab)

  2. Oncolytic Viruses in Lymphoma

    Lymphoma is a heterogenous disease accounting for 4% of all UK cancer diagnoses. Its overall response to chemotherapy is good. However, in patients with relapsed or refractory disease, less than half will obtain durable remissions. Anti CD20 targeting by monoclonal antibodies such as rituximab have …

    whiterose Download file for Oncolytic Viruses in Lymphoma (opens in a new tab)

  3. Burkitt lymphoma and diffuse large B-cell lymphoma – therapeutic strategies and pathogenetic mechanisms

    Burkitt lymphoma (BL) is a rare, aggressive disorder constituting 1% of all non-Hodgkin lymphoma. Diffuse large B-cell lymphoma (DLBCL) is more common, accounting for 30% of malignant lymphoma. Standard treatment for adult BL and for certain subgroups of patients with DLBCL remains to be defined …

    lund Repository record for Burkitt lymphoma and diffuse large B-cell lymphoma – therapeutic strategies and pathogenetic mechanisms (opens in a new tab) Download PDF for Burkitt lymphoma and diffuse large B-cell lymphoma – therapeutic strategies and pathogenetic mechanisms (opens in a new tab)

  4. The Biology of Mantle Cell Lymphoma: Exploring the Gender Difference in Mantle Cell Lymphoma

    Mantle cell lymphoma (MCL) is a rare B cell neoplasm that accounts for approximately 4-8% of non-Hodgkin’s lymphomas (NHLs). The median age at diagnosis is 65 years with a male to female predominance of 3:1. It has also been demonstrated that female MCL patients have a greater response to therapy, …

    plymouth Repository record for The Biology of Mantle Cell Lymphoma: Exploring the Gender Difference in Mantle Cell Lymphoma (opens in a new tab)

  5. Burkitt lymphoma classification and MYC-associated non-Burkitt lymphoma investigation based on gene expression

    Burkitt lymphoma and diffuse large B-cell lymphoma are two closely related types of lymphoma that are managed differently in clinical practice and the accurate diagnosis is a key point in treatment decisions. However based on current criteria combined with morphological, immunophenotypic and …

    whiterose Download PDF for Burkitt lymphoma classification and MYC-associated non-Burkitt lymphoma investigation based on gene expression (opens in a new tab)

  6. Molecular characterisation of canine lymphoma

    Lymphoma is the most common haematopoietic malignancy of dogs, but little is known about its aetiology and pathogenesis. Canine lymphoma is composed of a clinically heterogeneous group of tumours, as in human non-Hodgkin lymphoma (hNHL), which shares many similarities with the canine disease. In …

    glasgow

  7. Transcriptional profiling of aggressive lymphoma

    Lymphoma is the fifth most frequent cancer in North America and Western Europe. This thesis is concerned with transcriptional profiling of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) using supervised and semi-supervised machine learning methodology. It investigates two aspects …

    fu-berlin Repository record for Transcriptional profiling of aggressive lymphoma (opens in a new tab)

  8. The Role of NFATc1 in Burkitt Lymphoma and in Eµ-Myc induced B cell Lymphoma

    Burkitt lymphoma (BL) is a highly aggressive B cell malignancy. Rituximab, a humanized antibody against CD20, in a combination with chemotherapy is a current treatment of choice for B-cell lymphomas including BL. However, certain group of BL patients are resistant to Rituximab therapy. Therefore, …

    wurz-thes Repository record for The Role of NFATc1 in Burkitt Lymphoma and in Eµ-Myc induced B cell Lymphoma (opens in a new tab)

  9. Aberrant hypermethylation of Xq12 in lymphoma

    … located on the X chromosome in 84% of follicular lymphoma patient samples. Methylation has been shown to spread several megabases from its origin and this has led us to hypothesize that a candidate tumour suppressor gene is located in the vicinity ofthe AR. AR and the nearby oligophrenin (OPHNl) …

    ubc Repository record for Aberrant hypermethylation of Xq12 in lymphoma (opens in a new tab) Download PDF for Aberrant hypermethylation of Xq12 in lymphoma (opens in a new tab)

  10. Targeted therapies in mantle cell lymphoma

    Mantle cell lymphoma (MCL) is characterized by the presence of the t(11 ;14)(g13 ;g32) translocation which results in cyclin Dl over-expression. MCL is one of the most difficult lymphoproliferative disorders to manage with a median survival rate of 43 months from diagnosis. The poor prognosis …

    ubc Repository record for Targeted therapies in mantle cell lymphoma (opens in a new tab) Download PDF for Targeted therapies in mantle cell lymphoma (opens in a new tab)

  11. The molecular ontogeny of follicular lymphoma

    Background: Advanced-stage follicular lymphoma (FL) is considered incurable, with patients typically suffering from a chronic relapsing clinical course. Relapsed FL is thought to originate from common progenitor cells (CPCs) through divergent evolution. CPCs typically contain the hallmark BCL2/IGH …

    lmu-germany Repository record for The molecular ontogeny of follicular lymphoma (opens in a new tab)

  12. Fractionated radioimmunotherapy of non-Hodgkin's lymphoma

    <p>Impressive durable responses from clinical studies using higher myeloablative dose RIT followed by peripheral blood stem cell transplant (PBSCT) suggest that there may be a radiation dose response for RIT. With the development of rituximab, a chimeric mAb, multiple or fractionated treatments are …

    soton Download PDF for Fractionated radioimmunotherapy of non-Hodgkin's lymphoma (opens in a new tab)

  13. Therapeutic DNA vaccination in follicular lymphoma

    … in humans in patients with low-grade follicular lymphoma. Twenty-five patients were enrolled and the V genes encoding the V domains of their surface immunoglobulin (sIg) on the dominant malignant clone were isolated from a lymph node biopsy and single chain variable domain antibody fragments …

    the-open-u Download PDF for Therapeutic DNA vaccination in follicular lymphoma (opens in a new tab)

  14. Prognostication of Canine T Cell Lymphoma

    Canine lymphoma is a heterogeneous disease with many different subtypes. T cell lymphoma (TCL) is variable in outcome, and includes subtypes with non-progressive, indolent and aggressive disease course. Methods used to categorize lymphoma including cytopathology, flow cytometry, histopathology, and …

    guelph Repository record for Prognostication of Canine T Cell Lymphoma (opens in a new tab)

Page 1 of 96